WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Amgen
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Masters Speciality Pharma | January 18, 2017
Masters Speciality Pharma is pleased to announce its appointment as Amgen (Europe) GmbH’s exclusive supplier of XGEVA® (denosumab), Prolia® (denosumab) and Neupogen® (filgrastim), to government bodies, hospitals and Health Care Professionals in Azerbaijan, Costa Rica, Pakistan, Panama, Uruguay and Senegal....
European Pharmaceutical Review | April 27, 2017
Novartis has expanded their commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine....
FiercePharma | May 01, 2017
At January’s JPMorgan Healthcare Conference, Amgen CEO Robert Bradway proclaimed that his company would be “a clear beneficiary” of any corporate tax reform U.S. President Donald Trump could enact....
Pharma times | May 03, 2017
The Institute has published final draft guidance recommending Blincyto (blinatumomab) as an option for treating adults with Philadelphia-chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL), on the basis of the discount agreed in the patient access scheme....
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE
